ID: ALA4456692

Max Phase: Preclinical

Molecular Formula: C25H25F3N4O3

Molecular Weight: 486.49

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=C(O)[C@@H]1[C@@H]2C[C@H](OC3CCN(c4ccc(-c5nc6cc(C(F)(F)F)ccc6[nH]5)cn4)CC3)C[C@@H]21

Standard InChI:  InChI=1S/C25H25F3N4O3/c26-25(27,28)14-2-3-19-20(9-14)31-23(30-19)13-1-4-21(29-12-13)32-7-5-15(6-8-32)35-16-10-17-18(11-16)22(17)24(33)34/h1-4,9,12,15-18,22H,5-8,10-11H2,(H,30,31)(H,33,34)/t16-,17+,18-,22+

Standard InChI Key:  PVTQXWOCZXCWFB-XYGUIBQMSA-N

Associated Targets(Human)

Acyl coenzyme A:cholesterol acyltransferase 1 857 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Diacylglycerol O-acyltransferase 1 1719 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Diacylglycerol O-acyltransferase 1 342 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 486.49Molecular Weight (Monoisotopic): 486.1879AlogP: 4.74#Rotatable Bonds: 5
Polar Surface Area: 91.34Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.39CX Basic pKa: 6.34CX LogP: 2.24CX LogD: 1.30
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.54Np Likeness Score: -1.00

References

1. He S, Lai Z, Hong Q, Shang J, Reibarkh M, Kuethe JT, Liu J, Guiadeen D, Krikorian AD, Cernak TA, Dykstra KD, Sperbeck DM, Wu Z, Yu Y, Yang GX, Jian T, Verras A, Sonatore LM, Wiltsie J, Chung CC, Murphy BA, Gorski JN, Liu J, Xiao J, Wolff M, Tong SX, Madeira M, Karanam BV, Shen DM, Balkovec JM, Pinto S, Nargund RP, DeVita RJ..  (2019)  Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety.,  29  (10): [PMID:30926247] [10.1016/j.bmcl.2019.03.025]

Source